ArticleEndocrinology, diabetes & metabolism2026
Therapeutic Potential of Holothuria leucospilota Extract in STZ-Induced Diabetic Rats: Targeting Inflammation and Apoptosis at the Gene Expression Level.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Potential of Holothuria leucospilota Extract in STZ-Induced Diabetic Rats: Targeting Inflammation and Apoptosis at the Gene Expression Level.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic inflammation is a key contributor to diabetes pathogenesis. Marine-derived bioactive compounds offer a promising source of therapeutic agents. This study investigated the effects of Holothuria leucospilota n-hexane extract on biochemical and inflammatory markers in diabetic male rats. MATERIALS AND
methodsMale Wistar rats were divided into four groups: control, diabetic, and diabetic treated with H. leucospilota extract (100 or 200 mg/kg). Diabetes was induced by streptozotocin. Animals received daily intraperitoneal injections of saline or extract. One-third of the animals in each group (n = 8) were euthanised and sampled on days 1, 15, and 30. The extract composition was analysed by GC-MS. Serum glucose, insulin, amyloid beta, and expression of TGF-β, TNF-α, FasL, IL-10, and miR-146a were measured in blood, while leptin gene expression was assessed in liver samples.
resultsGC-MS revealed major compounds including olean-12-ene-3,28-diol (14.1%), cyclohexane derivatives (8.2%), oleic acid (4.8%), and cis-13-eicosenoic acid (4.2%). Diabetic rats showed elevated glucose, amyloid beta, leptin, TGF-β, TNF-α, and FasL levels, with reduced insulin, IL-10, and miR-146a levels compared to the control group. Treatment with H. leucospilota extract (100 and 200 mg/kg) significantly reversed these changes at both 15 and 30 days compared to the diabetic group.
conclusionH. leucospilota n-hexane extract improved biochemical and inflammatory markers in diabetic rats, suggesting its potential as a natural therapeutic agent to mitigate diabetes-associated inflammation and metabolic dysfunction. The identified bioactive compounds may underlie these beneficial effects, highlighting the therapeutic relevance of marine-derived extracts in diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.